Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motixafortide for Stem Cell Mobilization in Sickle Cell Disease
NCT06442761Phase 1Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Nov 2024
- Primary completion
- Jan 2028
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of motixafortide in sickle cell disease (SCD) (2 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoint: Incidence of Adverse Events at 30 days. Started Nov 2024; status: recruiting.
02
Drugs
motixafortide
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT06442761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06442761.